We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy

Expanded access is no longer available for this treatment.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01646593
First Posted: July 20, 2012
Last Update Posted: December 15, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Bayer
July 18, 2012
July 20, 2012
December 15, 2014
 
Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy

The objective of the trial is to provide regorafenib to subjects diagnosed with metastatic and / or unresectable GIST who have progressed after standard therapy.

Selected additional safety information on regorafenib will be collected and progression-free survival (PFS) will be estimated.

Not Provided
Expanded Access
Drug: Regorafenib (BAY73-4506)
160 mg BAY73-4506, 3 weeks on drug, 1 week off
Not Provided
 
No longer available
Contact information is only displayed when the study is recruiting subjects
Not Provided
United States
 
NCT01646593
Therapeutic Area Head, Bayer Healthcare AG
Bayer
Not Provided
Study Director: Bayer Study Director Bayer
Bayer
December 2014